Results 1 to 10 of about 2,857,482 (280)

Cytokine release syndrome [PDF]

Journal for ImmunoTherapy of Cancer, 2018
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody ...
Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll, Michael S. von Bergwelt-Baildon   +8 more
doaj   +11 more sources

Rituximab and Cytokine Release Syndrome [PDF]

Case Reports in Oncology, 2012
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated
Hrishikesh S. Kulkarni, Pashtoon Murtaza Kasi   +1 more
doaj   +5 more sources

Rituximab induced cytokine release syndrome in an MS patient: A case report

Clinical Case Reports, 2021
Cytokine release syndrome with rituximab has been reported in certain diseases, however, it is rarely reported in MS patients treated with rituximab. The treating physician should suspect the syndrome when typical signs and symptoms appear.
Masoud Etemadifar, Mehri Salari, Mahdieh Saeri, Amirhossein Akhavan Sigari, Sara Ebrahimi Pelarti   +4 more
doaj   +3 more sources

Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature

Clinical and Translational Radiation Oncology, 2022
We present the case of a 53-year-old woman treated with analgesic radiotherapy for a multiple myeloma bone lesion of the forearm. After a first fraction of 5 Gray (Gy), she presented with an acute respiratory syndrome with fever a few hours after the ...
Axel Cailleteau, Cyrille Touzeau, Bastien Jamet, Valentine Guimas, Emmanuel Jouglar, Stéphane Supiot   +5 more
doaj   +2 more sources

Cytokine release syndrome

Journal of Pediatric Critical Care
Cytokine release syndrome (CRS) is a severe, potentially life-threatening immune-mediated condition characterized by excessive cytokine secretion leading to systemic inflammation and multiorgan dysfunction.
Rachit Mehta, Indira Jayakumar
doaj   +3 more sources

Cytokine Release Syndrome: A Case Report. [PDF]

Cureus
Although generally well tolerated, immune checkpoint inhibitors can occasionally lead to severe immune-related adverse events, including cytokine release syndrome (CRS), a condition resulting from excessive immune activation and cytokine secretion, specifically interleukin-6 (IL-6).
Silva IF, Salgueira SG, Loureiro AI, Nascimento L, Gomes T.   +4 more
europepmc   +3 more sources

Cytokine release syndrome after bronchoalveolar lavage

BMC Pulmonary Medicine, 2023
Background Immunosuppressed bone marrow transplant patients with pulmonary infiltrates routinely undergo bronchoscopy with bronchoalveolar lavage (BAL) to investigate potential etiologies.
Margaret Guerriero, Feras Ally, Keith R. Loeb, Viswam S. Nair   +3 more
doaj   +3 more sources

Cytokine release syndrome in solid tumors. [PDF]

Cancer
AbstractCytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to ...
Synnott D, O'Reilly D, De Freitas D, Naidoo J.   +3 more
europepmc   +4 more sources

Cytokine Release Syndrome: Current Perspectives

ImmunoTargets and Therapy, 2019
Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa,
Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA   +3 more
doaj   +5 more sources

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

Diseases, 2022
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies.
Puri Ferreros, Isabel Trapero
doaj   +3 more sources